Equity Research is published in the framework of the Tel Aviv Stock Exchange (TASE) Analysis Program
TEL AVIV, Israel, Aug. 21, 2018 /PRNewswire/ -- Cellect Biotechnology Ltd. is developing a technological platform, the "ApoGraft", which functionally selects stem cells from a mixed population of cells based on their sensitivity to apoptosis. The first product under development is the ApoTainer™ selection kit. The company is currently conducting a proof-of-concept phase I/II trial with blood cancer patients in Israel, which is expected to be completed by the end of Q3-2018. Based on trial results and safety issues, the company plans to integrate its technology into a range of procedures that utilize stem cells, as well as into the manufacturing process of adult stem cell based products.
Summary of Highlights
Cellect released its Q2-2018 report on 9 August, 2018 detailing the following:
Cellect is on track with its strategic plans; minor setback in patient recruitment may delay ApoGraft POC final results till mid-2019.
Cellect has initiated a second program focusing on the selection of mesenchymal stem cells (MSCs) from fat cells, which poses great potential.
Sufficient cash to support current clinical early phase and other pre-clinical pipeline development until Q2-2019.
We maintain our estimation of the company's equity value at $101.4M; corresponding to a target price ranging between $15.40 and $18.70; a mean of $16.90.
Read the full report here.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Contact us: Start the discussion
Contact:
Jacqui Holmes
Corporate Communications - Frost & Sullivan, Europe
E: jacqui.holmes@frost.com
http://www.frost.com